Heart treatment startup passes Venture Kick stage 2
02.02.2018
Congratulations to HAYA Therapeutics selected by the jury to receive CHF 20,000.
 HAYA Therapeutics co-founder Samir Ounzain
|
 |
HAYA Therapeutics (UNIL) – bio-tech, bio-pharma:
HAYA Therapeutics is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs. The startup aims to be the first company and world leader in translating long noncoding RNA discoveries into breakthrough bench-to-bedside tools to monitor and treat heart failure patients.
HAYA Therapeutics is dedicated to treating heart failure through the discovery and development of innovative first-in-class RNA-based therapeutics, with a specific focus on long noncoding RNAs. The startup aims to be the first company and world leader in translating long noncoding RNA discoveries into breakthrough bench-to-bedside tools to monitor and treat heart failure patients.